Glen Eagle Advisors, LLC Editas Medicine, Inc. Transaction History

Glen Eagle Advisors, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Aug 13, 2024	SELL	$26.55 - $40.57 $1,062 - $1,622	-40 Closed	0 $0
Q3 2021 Aug 13, 2024	BUY	$39.27 - $72.94 $1,570 - $2,917	40 New	40 $1.64 Million
Q3 2020 Aug 13, 2024	SELL	$28.06 - $37.16 $2,104 - $2,786	-75 Closed	0 $0
Q1 2019 Aug 13, 2024	BUY	$19.43 - $26.41 $1,457 - $1,980	75 New	75 $1.83 Million
Q3 2018 Aug 13, 2024	BUY	$27.65 - $38.39 $2,073 - $2,879	75 New	75 $2.39 Million

249

56.9M

410K

394K

Ticker EDIT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 68,737,200
Market Cap $96.9M
Description
Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis 10 that leads t...

Get notified when there are updates to the investment portfolio of Glen Eagle Advisors, LLC, based on Form 13F filings with the SEC.

Stay updated on Glen Eagle Advisors, LLC with notifications on news.